Rotavirus A serotype G4 (G4)

Rotavirus A serotype G4 is a specific antigenic variant of the Rotavirus A species, defined by the molecular characteristics of its VP7 outer capsid glycoprotein. It is recognized as one of the five most prevalent global serotypes responsible for severe, dehydrating gastroenteritis in infants and young children [1]. The virus primarily targets mature enterocytes in the small intestine, where it replicates and utilizes the non-structural protein NSP4 as an enterotoxin to induce secretory diarrhea [2]. In the context of drug and vaccine development, G4 is a critical target for multi-valent vaccines such as RotaTeq, which utilizes a human-bovine reassortant strain to provide specific immunity against this serotype [3]. These therapeutic interventions aim to elicit neutralizing antibodies that block viral entry and reduce the severity of clinical infection [4]. Continuous epidemiological monitoring of G4 is essential due to the virus's ability to undergo genetic reassortment, which can lead to the emergence of novel strains that may bypass existing vaccine-induced immunity [5].

Other names

G4 rotavirusRotavirus A G4VP7 serotype G4Human rotavirus G4G4P[8] rotavirus

Vaccines induce neutralizing antibodies against the VP7 (G-type) and VP4 (P-type) surface proteins to prevent viral attachment and entry into host enterocytes. Antiviral agents like nitazoxanide inhibit viral replication by interfering with the maturation of viral proteins and the formation of the viroplasm.